头孢哌酮钠舒巴坦钠治疗慢性阻塞性肺疾病急性发病期的效果  

Effect of cefoperazone sodium and sulbactam sodium on acute exacerbations of chronic obstructive pulmonary disease

作　　者：张向东 ZHANG Xiang-dong(Xingcheng People’s Hospital,Xingcheng 125100,China)

机构地区：[1]辽宁省兴城市人民医院,125100

出　　处：《中国实用医药》2022年第2期125-127,共3页China Practical Medicine

摘　　要：目的观察慢性阻塞性肺疾病急性发病期患者实施头孢哌酮钠舒巴坦钠治疗的临床效果。方法98例慢性阻塞性肺疾病急性发病期患者,按照治疗方案的不同分为观察组与对照组,每组49例。观察组给予头孢哌酮钠舒巴坦钠治疗,对照组给予头孢他啶治疗。比较两组患者的临床治疗效果,不良反应发生情况。结果观察组患者的治疗总有效率为97.96%,高于对照组的85.71%,差异具有统计学意义(P<0.05)。观察组患者的不良反应发生率为2.04%,低于对照组的6.12%,但差异无统计学意义(P>0.05)。结论慢性阻塞性肺疾病急性发病期患者实施头孢哌酮钠舒巴坦钠治疗,在病情改善、肺功能提升方面作用显著,且用药安全性较高,值得推荐。Objective To observe the clinical effect of cefoperazone sodium and sulbactam sodium on acute exacerbations of chronic obstructive pulmonary disease.Methods A total of 98 patients with acute exacerbations of chronic obstructive pulmonary disease were divided into observation group and control group according to different treatment regimens,with 49 cases in each group.The observation group was treated with cefoperazone sodium and sulbactam sodium,and the control group was treated with ceftazidime.The clinical effect and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 97.96%,which was higher than 85.71%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 2.04%,which was lower than 6.12%in the control group,but the difference was not statistically significant(P>0.05).Conclusion The implementation of cefoperazone sodium and sulbactam sodium in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease has a significant effect on the improvement of condition and pulmonary function,and the drug safety is high,so the scheme is worth recommending.

关 键 词：慢性阻塞性肺疾病 急性发病期 头孢哌酮钠舒巴坦钠 临床效果 

分 类 号：R563.9[医药卫生—呼吸系统]